Covance

Covance Posts 11% Revenue Growth

Thursday, October 23, 2008 04:05 PM

Although Princeton, N.J., CRO Covance experienced a number of third quarter cancellations and project delays, the company posted 11.1% revenue growth for the third quarter. Profit rose 15% to $51.1 million, or $0.80 per diluted share.

More... »

CenterWatch Monthly October 2008

Friday, October 3, 2008 02:44 PM

Trio of Companies in Strategic Outsourcing Partnerships with Lilly

More... »

China-based WuXi Reports Successful Second Quarter

Tuesday, August 19, 2008 11:18 AM

A year after going public on the New York Stock Exchange, Chinese contract research, development and manufacturing company WuXi PharmaTech reported second quarter net revenues of $70.8 million—a 134% increase compared with the same period last year.

More... »

Covance, Lilly Deal Grows on CRO Industry

Friday, August 8, 2008 05:00 PM

Earlier this week, we reported news about the Covance-Lilly $1.6-billion deal, but Clinicaltrialstoday.com has learned additional details about the blockbuster transaction between the contract research organization (CRO) and major pharma company from interviews and Wednesday’s investor conference call.

More... »

Kendle's Global CRO Growth Story Continues with Record Quarter

Thursday, August 7, 2008 07:30 AM

On a day when contract research organization (CRO) Covance announced a blockbuster $1.6 billion deal with Eli Lilly, the global CRO growth story got another big boost when Kendle reported record financial results for its second quarter.

More... »

Covance in Groundbreaking $1.6 Billion Drug Development Services Deal with Eli Lilly

Wednesday, August 6, 2008 09:44 AM

Covance, a leading global contract research organization (CRO), signed a definitive agreement today with Eli Lilly that is designed to help transform Lilly’s R&D model.

More... »

Covance Reports 23% Earnings Growth in 2Q

Thursday, July 31, 2008 09:59 AM

Covance reported after the bell Wednesday that its second quarter earnings jumped 22.7% to 79 cents per diluted share compared with the second quarter of 2007. The contract research organization said the earnings excluded one cent per share gain from the sale of its centralized ECG business in 2007.

More... »

Covance Reports Jump in Fourth Quarter Revenue

Friday, February 8, 2008 01:55 PM

Princeton, N.J.-based CRO Covance reported a nearly 20% jump in fourth quarter net revenue to $411 million compared with $343 million in 2006. Net income was also impressive, $47 million, a 22% increase compared with the fourth quarter of 2006. Earnings per share were $0.72 in the quarter, up 21.8% compared with the fourth quarter of 2006. Fourth quarter revenues were split evenly between Covance’s early development and late-stage development business units.

More... »

Covance Boosts Phase I/IIa Capacity

Sunday, April 30, 2006 11:18 AM

The search for top quality phase I sites just got even harder as Covance, a leader in the hot early clinical development arena, entered into a definitive agreement to acquire eight early phase clinical development sites from Radiant Research, a site management organization that owns 30 sites, for $65 million. Covance is paying about 2.5 times revenue for the eight sites, which generate $25 million in annual revenue. Seattle-based Radiant Research will continue to operate its phase II through IV sites,but employees associated with the eight phase I sites will become Covance employees. Covance, one of the top global contract research organizations (CROs), has more than 7,300 employees worldwide.

More... »

A Stock Split Can Make You Forget

Wednesday, February 15, 2006 11:06 AM

PPD's two-for-one stock split is good news for the top global clinical  research organizations. Investors attracted to the sector by the  company's split announcement Feb. 8 can focus on PPD and other top CROs  rather than the sideshow embattled SFBC has become. When new investors look at top CROs such as PPD, Quintiles , PRA, ICON, Parexel and Covance, they will see the pharmaceutical outsourcing industry  ready to consolidate around a handful or so of these companies.These  global CROs have a big advantage over the estimated 1,000 other small  CROs throughout the world. They have international infrastructure in  place to conduct complex clinical trials in thousands of patients at  sites across multiple countries.That global presence is not easy to  build and represents a barrier to entry for small CROs trying to roll  up into a global player.

More... »